Fasting Study of Metolazone Tablets 2.5 mg and Zaroloxyn® Tablets 2.5 mg

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2002
The objective of this study was to investigate the bioequivalence of Mylan metolazone 2.5 mg tablets to Celltech Zaroxolyn® 2.5 mg tablets following a single, oral 10 mg (4 x 2.5 mg) dose administration under fasting conditions.
Epistemonikos ID: b84099d02d5559381aabce3f417f2cb41436f5a0
First added on: May 04, 2024